Norja - norja - Statens legemiddelverk

orifarm as - kalsiumkarbonat / kolekalsiferol - tyggetablett - 500 mg / 800 ie

Norja - norja - Statens legemiddelverk

orifarm as - kalsiumkarbonat / kolekalsiferol - tyggetablett - 1000 mg / 800 ie

Norja - norja - Statens legemiddelverk

2care4 aps - kalsiumkarbonat / kolekalsiferol - tyggetablett - 1000 mg / 800 ie

Norja - norja - Statens legemiddelverk

2care4 aps - kalsiumkarbonat / kolekalsiferol - tyggetablett - 1000 mg / 800 ie

Norja - norja - Statens legemiddelverk

2care4 aps - kalsiumkarbonat / kolekalsiferol - tyggetablett - 1000 mg / 800 ie

Norja - norja - Statens legemiddelverk

2care4 - kalsiumkarbonat / kolekalsiferol - tyggetablett - 1000 mg / 800 ie

Norja - norja - Statens legemiddelverk

sanofi pasteur europe - influensa a-virus (h1n1), inaktivert, splittvirus / influensa a-virus (h3n2), inaktivert, splittvirus / influensa b-virus, victoria-linje, inaktivert, splittvirus / influensa b-virus, yamagata-linje, inaktivert, splittvirus - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 15 mikrog ha / 15 mikrog ha / 15 mikrog ha / 15 mikrog ha

Norja - norja - Statens legemiddelverk

paranova as - kalsiumkarbonat / kolekalsiferol - tyggetablett - 1000 mg / 800 ie

Euroopan unioni - norja - EMA (European Medicines Agency)

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastiske midler - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.

Euroopan unioni - norja - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastiske midler - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.